Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (Nasdaq: LUMO) is a clinical-stage biotechnology company dedicated to developing innovative therapeutics for rare diseases. Headquartered in the United States, Lumos Pharma focuses on creating treatments for conditions such as cancer and rare growth disorders. The company is active in both clinical-stage and preclinical research, emphasizing molecules that enhance the immune system's ability to fight cancer cells.
The company's portfolio includes orally administered treatments, designed to be used alongside other cancer therapies, and a promising Ebola vaccine. Recent achievements highlight the company's progress in its clinical trials, particularly the Phase 2 trials evaluating LUM-201 for moderate Pediatric Growth Hormone Deficiency (PGHD), which have shown significant results in increasing annualized height velocity (AHV). These advancements underscore Lumos Pharma's commitment to addressing unmet medical needs.
Lumos Pharma engages in strategic partnerships with pharmaceutical companies and contracts with manufacturing organizations to ensure the effective production of its treatments. A notable recent development is the appointment of Dr. Pitukcheewanont as Chief Medical Officer. Dr. Duke, with extensive experience in clinical development and medical affairs, has been integral in the advancement of Lumos Pharma's clinical programs.
Financially, Lumos Pharma is in a stable position, with cash on hand expected to support operations through Q3 2024. The company is also gearing up for a Phase 3 trial for LUM-201, poised to be a double-blinded, placebo-controlled clinical trial with a 2:1 randomization in approximately 150 patients. This trial aims to secure the approval of LUM-201 as the first oral therapeutic for moderate PGHD.
Lumos Pharma continues to exhibit its potential through its robust research initiatives, strategic partnerships, and a dedicated team of experts. The company's proactive approach in clinical and preclinical development projects positions it as a significant player in the biotechnology sector, particularly in the realm of rare diseases.
Lumos Pharma presented new analyses from Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials at ESPE 2024. The data showed sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) patients over 24 months. Results demonstrated significant increases in Annualized Height Velocity (AHV) from baseline 4.6 cm/yr to 7.8 cm/yr at 6 months, maintaining 7.3 cm/yr at 24 months. The studies also showed notable improvements in IGF-1 levels from 13.1 to 29.2 nmol/L and IGFBP-3 from 133.5 to 186.2 nmol/L over 24 months. Additional analysis revealed correlation between pulsatile growth hormone secretion patterns and growth responses to LUM-201 treatment.
Lumos Pharma (NASDAQ:LUMO) announced that two abstracts featuring analyses from their Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting (ESPE 2024). The presentations, scheduled for November 17-18, 2024 in Liverpool, UK, will focus on LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD). The abstracts will cover growth responses and hormone secretion patterns in PGHD patients over 12-24 months of treatment.
Lumos Pharma, Inc. (NASDAQ:LUMO) announced that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024). The event will take place from October 2-5, 2024, in New Delhi, India.
The presentation, scheduled for October 3rd, will focus on the evaluation of oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD). Professor Paul Hofman, MD, from the Liggins Institute, University of Auckland, New Zealand, will deliver the presentation titled 'Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial'.
Lumos Pharma (NASDAQ:LUMO) announced the acceptance of an abstract for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (SLEP 2024) in Santiago, Chile. The abstract, titled 'LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials', will be presented as an e-poster on September 13, 2024. This presentation will feature an updated analysis of data from Lumos Pharma's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials, focusing on their therapeutic candidate for rare diseases.
Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focusing on rare disease therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. The company's management will be available for one-on-one meetings on September 9th and 10th.
Key details include:
- An on-demand corporate presentation available from September 9th at 7:00 AM EDT
- A webcast accessible for 90 days after the event
- The presentation will also be available on Lumos Pharma's website
Investors can contact H.C. Wainwright sales representatives or Lumos Pharma's Investor Relations to schedule meetings with management during or after the conference.
Lumos Pharma (NASDAQ:LUMO) reported Q2 2024 financial results and provided a clinical update. Key highlights include:
1. Advancing plans for a Phase 3 placebo-controlled trial of LUM-201 in moderate pediatric growth hormone deficiency, expected to initiate in Q2 2025.
2. Cash position of $16.8 million as of June 30, 2024, sufficient to support operations into Q1 2025.
3. Q2 2024 net loss of $7.6 million, compared to $8.9 million in Q2 2023.
4. R&D expenses decreased to $4.6 million, while G&A expenses reduced to $3.7 million.
5. Presented new analyses of OraGrowtH212 Trial data at ENDO 2024, supporting LUM-201's unique mechanism of action.
Lumos Pharma (NASDAQ:LUMO), a late-stage biopharmaceutical company focusing on rare disease therapeutics, has announced it will report its second quarter 2024 financial results after market close on August 1, 2024. The company will host a conference call and webcast at 4:30pm ET the same day to discuss these results and provide updates on clinical and corporate activities.
The call will include a question-and-answer session following prepared remarks. Participants can join via phone or webcast, with dial-in registration available 15 minutes before the scheduled start time. A replay of the call will be accessible through the company's website after the event.
Lumos Pharma presented new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 meeting. The data reveals that oral LUM-201 significantly increased growth hormone (GH) secretion in children with moderate Pediatric Growth Hormone Deficiency (PGHD) over six months. The treatment restored GH levels to near-normal compared to healthy children, with lower GH exposure than traditional rhGH injections. This supports Lumos Pharma's plans for a Phase 3 trial. Results showed GH secretion increased from 0.19 to 0.36 μg/kg/12-hrs at 1.6 mg/kg/day dose and from 1.17 to 1.8 μg/kg/12-hrs for pulsatile GH. The data suggests a positive correlation between growth response and GH pulsatility patterns.
Lumos Pharma announced that new analyses from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials will be presented at the 2024 Annual Meeting of the Endocrine Society (ENDO) in Boston from June 1-4, 2024.
The two posters cover significant findings in pediatric growth hormone deficiency treatments. The first, presented by Dr. Fernando Cassorla, focuses on oral LUM-201 and its ability to restore growth hormone secretion in children. The second, by Dr. Adam Stevens, examines how growth responses to LUM-201 depend on the pattern of hormone secretion.
Lumos Pharma reported positive outcomes from its End-of-Phase 2 meeting with the FDA, supporting a placebo-controlled Phase 3 trial of LUM-201. The company shared promising 12 and 24-month data from Phase 2 OraGrowtH trials, showing significant growth increases from baseline. Full 12-month data demonstrated AHVs of 8.2 cm/yr and 7.6 cm/yr at 6 and 12 months, respectively. Financially, Lumos Pharma reported a net loss of $10.4 million for Q1 2024, with cash reserves of $23.2 million, expected to support operations through Q3 2024. R&D expenses rose to $7.2 million, while G&A expenses decreased to $3.8 million.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
What does Lumos Pharma, Inc. specialize in?
What are some of the key products in Lumos Pharma's pipeline?
Where is Lumos Pharma headquartered?
What is the status of Lumos Pharma's clinical trials?
Who is the Chief Medical Officer of Lumos Pharma?
What partnerships does Lumos Pharma engage in?
What is the financial outlook for Lumos Pharma?
What is LUM-201?
Does Lumos Pharma conduct preclinical research?
How does Lumos Pharma's research contribute to cancer treatment?
